Literature DB >> 7941324

Role of anisomorphic DNA conformations in the negative regulation of a herpes simplex virus type 1 promoter.

R T Sarisky1, P C Weber.   

Abstract

The a sequence is a bifunctional element in the herpes simplex virus type 1 (HSV-1) genome which possesses both the signals required for the cleavage and encapsidation of replicated viral DNA and the promoter-regulatory sequences for the gene encoding the viral neurovirulence factor ICP34.5. Since the ICP34.5 promoter lacks features that are characteristic of most HSV-1 promoters, including a canonical TATA box, an initiator element, and upstream binding sites for host cell transcription factors, a mutational analysis was undertaken to identify the cis-acting elements which mediate transcription of this gene in transient transfection assays. A deletion derivative containing sequences just 83 nucleotides upstream of the second of two cap sites was found to exhibit full promoter activity. However, the presence of either of two far upstream regions, which coincided with the DR2 and DR6 tandem GC-rich repeat arrays, acted to abrogate transcriptional activity both in this segment of the ICP34.5 promoter and in a heterologous promoter construct. The DR2 and DR6 repeat arrays each possessed an unwound S1 nuclease-sensitive DNA conformation (anisomorphic DNA) whose formation was shown to be critical for mediating this transcriptional repression effect. Moreover, results from in vivo titration experiments suggested the existence of a cellular protein(s) which can mediate transcriptional repression in the ICP34.5 promoter by specifically interacting with the single-stranded regions of these tandem repeat arrays. Such DNA conformation-dependent transcriptional silencing appears to represent a novel mechanism of gene regulation in the HSV-1 life cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7941324     DOI: 10.1006/viro.1994.1571

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Cleavage in and around the DR1 element of the A sequence of herpes simplex virus type 1 relevant to the excision of DNA fragments with length corresponding to one and two units of the A sequence.

Authors:  K Umene
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Functional identification and analysis of cis-acting sequences which mediate genome cleavage and packaging in human herpesvirus 6.

Authors:  H Deng; S Dewhurst
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.

Authors:  Mohamed I Khalil; Marvin Sommer; Ann Arvin; John Hay; William T Ruyechan
Journal:  Virology       Date:  2013-03-21       Impact factor: 3.616

5.  The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation.

Authors:  G C Perng; K Chokephaibulkit; R L Thompson; N M Sawtell; S M Slanina; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity.

Authors:  P Secchiero; J Nicholas; H Deng; T Xiaopeng; N van Loon; V R Ruvolo; Z N Berneman; M S Reitz; S Dewhurst
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Assessing the contribution of the herpes simplex virus DNA polymerase to spontaneous mutations.

Authors:  Karen E Duffy; Matthew R Quail; Tammy T Nguyen; Robert J Wittrock; Joan O Bartus; Wendy M Halsey; Jeffry J Leary; Teresa H Bacon; Robert T Sarisky
Journal:  BMC Infect Dis       Date:  2002-05-07       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.